A $21/share offer for Covetrus Inc. (NASDAQ:CVET) from Clayton, Dubilier & Rice appears to be a "relatively modest" price, according to Stifel. Covetrus rose 11%. The $21 offer implies a purchase price of 14x 2022E EBITDA or 10-11x for the underlying distributor business if its assigned a 19-21x EBITDA multiple for the "faster" growing (20%+) and scaling Prescription Management and (Software) businesses, Stifel analyst Jonathan Block, who has a buy rating and $22 price target on CVET, wrote. CD&R already owns ~24% of Covetrus shares outstanding.